Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study
Genetically proxied lipid-lowering therapies are significantly associated with reduced risk of AS. Early initiation and sustained administration of lipid-lowering therapies may prevent AS progression and warrants further research in the clinical trial setting.
Authors
- Jonathan Ciofani (ORCID: https://orcid.org/0000-0003-4476-6051)
- Kazem Rahimi (ORCID: https://orcid.org/0000-0002-4807-4610)
- Benjamin Woolf (ORCID: https://orcid.org/0000-0002-1505-2570)
- Daniel Han (ORCID: https://orcid.org/0000-0002-9088-1651)
- U. Allahwala (ORCID: https://orcid.org/0000-0001-7178-4744)
- Dipender Gill (ORCID: https://orcid.org/0000-0001-7312-7078)
- Karan Rao (ORCID: https://orcid.org/0000-0003-4689-9982)
- Ravinay Bhindi
Institutions
- The University of Sydney (AU)
- University of Cambridge (GB)
- Royal North Shore Hospital (AU)
- Martin University (US)
- UNSW Sydney (AU)
- National Institute for Health and Care Research (GB)
- University of Bristol (GB)
- University of Oxford (GB)
- Cooperative Trials Group for Neuro-Oncology (AU)
- Oxford Biomedical Research (US)
- MRC Biostatistics Unit (GB)
- Imperial College London (GB)
Publication Details
- Journal
- European Heart Journal - Cardiovascular Pharmacotherapy
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1093/ehjcvp/pvae092
- Citations
- 7
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.81
Funders
- AstraZeneca
- Heart Research Australia
- UK Research and Innovation
- National Institute for Health and Care Research
- British Heart Foundation
- University of Oxford
- Novo Nordisk
- HORIZON EUROPE Framework Programme